Advanced diffuse large-cell lymphoma treated with 12-week combination chemotherapy: Natural history of relapse after initial complete response and prognostic variables defining outcome after relapse

Annals of Oncology

Volumn 8, Issue 11, 1997, Pages 1125-1132

  Hoskins, P J ^a,b   Le, N ^a   Gascoyne, R D ^a   Klasa, R ^a   Shenkier, T ^a   O'Reilly, S ^a   Connors, J M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Lymphoma; Relapse

Indexed keywords

BLEOMYCIN; CIMETIDINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; KETOCONAZOLE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; LEUCOVORIN; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; VINCRISTINE;

EID: 0030666522     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008263602334     Document Type: Article

References (25)

1. Weick JK, Dahlberg S, Fisher RI et al. Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: A Southwest Oncology Group Study. J Clin Oncol 1991; 9: 748-53.
2. Longo DT, Devita VT, Duffey PL et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J Clin Oncol 1991; 9: 25-38.
3. Dana BW, Dahlberg S, Miller TP et al. m-BACOD treatment for intermediate and high grade malignant lymphomas; A Southwest Oncology Group phase II trial. J Clin Oncol 1990; 8: 1155-62.
4. Fisher RI, Miller TP, Dana BW et al. Southwest Oncology Group clinical trials for intermediate and high grade non-Hodgkin's lymphoma. Semin Haematol 1987; 24: 21-5.
5. Fisher RI, Gaynor ER, Dahlberg W et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-6.
6. Coiffier B, Gisselbrecht C, Herbrecht R et al. LNH-84 Regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 19889; 7: 1018-26.
7. Cabanillas F, Velasquez WS, Hagenmeister FB et al. Clinical, biological and histologic features of late relapses in diffuse large cell lymphoma. Blood 1992; 79: 1024-8.
8. Shipp MA, Yeap BY, Harrington DP et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma. Analysis of the complete trial and comparison with the M-BACOD regimen. J Clin Oncol 1990; 8: 84-93.
9. Coltman CA, Dahlberg S, Iches SE et al. CHOP is curative in thirty percent of patients with large cell lymphoma. A twelve year Southwest Oncology Group follow-up. In Skarin AT (ed): Update on Treatment for Diffuse Large Cell Lymphoma. New York: Park Row 1986; 71-81.
10. Philip T, Hagenbeek A, Gomez F et al. Salvage treatment for chemotherapy resistant diffuse non-Hodgkin's lymphoma (NHL). Review of the 215 patients of the Parma study and rationale for a second prospective study. Ann Oncol 1986; 7 (Suppl 3): 17 (Abstr 54).
11. Bosly A, Coiffier B, Gisselbrecht C et al. Bone marrow transplantation prolongs survival after relapse in aggressive lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 1992; 10: 1615-23.
12. Blay J-Y, Gomez F, Bachelot T et al. The international prognostic index correlates to survival in intermediate/high grade lymphoma (NHL) in relapse: Analysis of the Parma trial. Proc Am Soc Clin Oncol 1996; 15: 151 (Abstr 269).
13. Hoskins P, Connors JM, Gascoyne R et al. 10-year outcome of 12-week duration chemotherapy for advanced large-cell lymphoma: The Vancouver experience. Ann Oncol 1996; 7: 58 (Abstr 198).
14. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: Wiley 1980.
15. Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphoma. Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-35.
16. Marazuela M, Yebra M, Giron JA et al. Late relapse with nodular lymphoma after treatment for diffuse non-Hodgkin's lymphoma. Cancer 1991; 67: 1950-3.
17. Siegel RD, Skarin AT, Canellos GP. Relapse with nodular lymphoma following combination chemotherapy for diffuse non-Hodgkin's lymphoma. Am J Clin Oncol 1986; 9: 420-3.
18. O'Brien CJ, Howard M, Child JA. Downgrading of non-Hodgkin's lymphoma following chemotherapy. Acta Haematol 1987; 77: 57-9.
19. Head DR, Avakian J, Kjeklsberg R, Cerezo L. Relapse of intermediate or high-grade (unfavorable) non-Hodgkin's lymphoma as a low-grade (favorable) non-Hodgkin's lymphoma. Am J Clin Pathol 1988; 289: 106-8.
20. Cheragan DP, Four K, Dressler L. High grade non-Hodgkin's lymphoma relapsing as low-grade follicular lymphoma. So-called downgraded lymphoma. Am J Hematol 1989; 30: 36-4.
21. Mead GM, Mackintosh FR, Burke JS, Rosenberg SA. Late relapse from complete remission in nodular and diffuse histiocytic lymphoma. Cancer 1983; 52: 1356-9.
22. Fisher RI, Jones RB, DeVita VT et al. Natural history of malignant lymphomas with divergent histologies at staging evaluation. Cancer 1981; 47: 2022-5.
23. Lee AYY, Connors JM, Klimo P et al. Late relapse in patients with diffuse large cell lymphoma treated with MACOP-B. J Clin Oncol 1997; 15: 1445-1753.
24. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-5.
25. The International Non-Hodgkin's lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94.